Single Ascending Oral Dose Phase I Study With Px-102

The study is a single-centre, double-blind, randomized, placebo-controlled, parallel group phase I study with healthy male subjects receiving ascending single oral oral doses of Px-102 to assess the safety and tolerability, pharmacokinetics and pharmacodynamics.

Inclusion criteria

• Healthy male subject of caucasian origin 18 to 45 years of age
• Good state of health (mentally and physically) as determined by medical history, physical examination, vital signs, ECG recording and clinical lab results.
• BMI in between 20-29 kg/m² with absolute weight in between 70-120 kg.
• Serum triglyceride, total cholesterol and liver enzyme levels (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (AP)) strictly within the normal ranges at screening and on Day -1.
• HbA1c ≤ 6.5 %
• Subject has been informed both verbally and in writing and has given written consent to participation in the study prior to start and any study-related procedure
• Negative results for HIV- and Hepatitis-B and -C serology at screening

Exclusion criteria

• Female gender
• Use of prescription or non-prescription drugs within 7 days (30 if the drug is a possible enzyme inducer) prior to administration of study medication. Use of drugs known to induce steatosis (e.g. valproate, amiodarone or prednisone) or to affect body weight and carbohydrate metabolism
• Any acute or chronic illness or clinically relevant finding at screening and at base line examination which may jeopardize the subject's participation in the study
• History or presence of biliary obstruction or biliary disease, hepatic encephalopathy, advanced ascites, portal hypertension, esophageal/gastric variceal bleeding, hepatocellular carcinoma, previous liver transplantation or any other chronic liver disease
• Renal dysfunction, e.g. glomerular filtration rate ≤ 80 ml/min/1,73m2 (as determined by the formula of Cockroft-Gault)
• Type I or II Diabetes
• Any clinically relevant abnormality on screening medical assessment, laboratory examination, 12-lead ECG Any clinically relevant finding in the baseline telemetry
• Marked baseline prolongation of QT/QTc interval (QTc interval > 440 ms) in the 12-lead ECG using the Fridericia method for QTc analysis
• Heart rate < 50 bpm.
• Allergies (except for mild forms of hay fever) or history of hypersensitivity reactions
• Smoking (regular or irregular) > 5 cigarettes (or equivalent) per day.
• Excessive alcohol drinking (more than approximately 20 g alcohol per day), unable to refrain from alcohol drinking from 48 h prior to dosing until the last pharmacokinetic blood sample has been withdrawn
• Positive test for drugs or alcohol at screening or prior to the dosing session
• History of alcoholism or drug/chemical/substance abuse within past 2 years
• Investigator deems the subject unable or unwilling to comply fully with the study protocol
• Has received clinical study medication within the last 30 days prior to this study
• Donation or loss of 400 ml or more of blood within eight (8) weeks prior to dosing
• Allergic to any of the active or inactive ingredients in the study medication
• Any other reason which the Investigator considers unsuitable for the subject to participate
• All subjects (including male subjects with partners of childbearing potential) who do not use a highly effective method of birth control (failure rate less than 1 % per year when used consistently and correctly), e.g. implants, injectables, combined oral contraceptives in combination with a barrier method, some intrauterine contraceptive devices or sexual abstinence
• Any condition or previous disease leading to puritus or itching of the skin.